ELMD
Electromed, Inc.
ELMD has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
ELMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
ELMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ELMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $24.97 | — |
| Cheap | 25x | $34.57 | +38% |
| Fair | 31x | $43.15 | +73% |
| Expensive | 44x | $60.28 | +141% |
Historical ranges are pointers, not guarantees.
ELMD has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ELMD Forward outlook
There aren't enough analyst estimates for ELMD to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ELMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.37 | +46% |
| Q2 2026 | $1.30 | +53% |
| Q1 2026 | $1.18 | +49% |
| Q4 2025 | $1.04 | +39% |
| Q3 2025 | $0.94 | +31% |
| Q2 2025 | $0.85 | +47% |
| Q1 2025 | $0.79 | +58% |
| Q4 2024 | $0.75 | +67% |
ELMD has the edge over NVO on earnings, with stronger typical year-over-year growth.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ELMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7M | +11% |
| Q2 2026 | $19.4M | +12% |
| Q1 2026 | $18.6M | +18% |
| Q4 2025 | $18.9M | +16% |
| Q3 2025 | $16.9M | +15% |
| Q2 2025 | $17.4M | +17% |
| Q1 2025 | $15.7M | +13% |
| Q4 2024 | $16.3M | +19% |
ELMD's revenue has grown year over year every quarter since late 2020: $19M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2.9 points |
| Q2 2026 | 20% | +2.2 points |
| Q1 2026 | 20% | +6.6 points |
| Q4 2025 | 19% | +3.5 points |
| Q3 2025 | 16% | +2.6 points |
| Q2 2025 | 17% | +1.7 points |
| Q1 2025 | 14% | +0.4 points |
| Q4 2024 | 16% | -0.9 points |
ELMD's operating margin was 19% last quarter, up 2.9 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ELMD on profitability, with a higher operating margin.
ELMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $208K | +$291K |
| Q2 2026 | $2.8M | -25% |
| Q1 2026 | $3.3M | +49% |
| Q4 2025 | $2.4M | -18% |
| Q3 2025 | -$83K | -104% |
| Q2 2025 | $3.7M | -17% |
| Q1 2025 | $2.2M | +76% |
| Q4 2024 | $2.9M | -14% |
ELMD generated $9M in free cash flow over the past year, about the same as the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ELMD on cash flow, with more consistent year-over-year improvement.
ELMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +72.8K shares |
| 1 year | +0.9% | +79.7K shares |
| 3 years | -0.2% | -21.4K shares |
| 5 years | -1.4% | -123K shares |
| Available history | 0% | +2.3K shares |
ELMD has 9M diluted shares, up 0.9% from a year ago, despite $7M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.3M |
| Q2 2026 | — |
| Q1 2026 | $152,000 |
| Q4 2025 | $2.8M |
| Q3 2025 | $1M |
| Q2 2025 | $3.7M |
| Q1 2025 | $1.8M |
| Q4 2024 | — |
ELMD spent $7M buying back its own shares over the past year, up 12% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ELMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ELMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.7x | Net Cash |
ELMD has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ELMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.8 | Neutral |
| Stochastic | 7.0 | Oversold |
ELMD's weekly RSI is 36 (neutral) and its Stochastic is 7 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ELMD PE vs Healthcare Sector
| Metric | ELMD | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 1 | 29 | 28 pts below |
ELMD is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ELMD on valuation relative to its sector.
ELMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.1 | 7.8% below |
| 20 week MA | $33.2 | 25% below |
| 50 week MA | $30.7 | 19% below |
| 100 week MA | $27.5 | 9.3% below |
| 200 week MA | $20.9 | 20% above |
ELMD has fallen below most of its moving averages, though it's still 20% above its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ELMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.57 | $9.99 | +17% |
| 2021 | $9.99 | $12.7 | +27% |
| 2022 | $12.7 | $9.89 | -22% |
| 2023 | $9.89 | $10.9 | +10% |
| 2024 | $10.9 | $29.2 | +168% |
| 2025 | $29.2 | $28.5 | -2.5% |
| 2026 YTD | $28.5 | $25.0 | -12% |
ELMD has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.